ClinicalTrials.gg
WithdrawnNCT06594523FASCINATE-3Updated May 15, 2025

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

A Phase 3 interventional study of Denifanstat and Placebo in MASH, NASH and Metabolic Dysfunction-associated Steatohepatitis, sponsored by Sagimet Biosciences Inc.. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Sagimet Biosciences Inc. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression without the worsening of steatohepatitis.

Read the detailed description

Approximately 1260 patients (including at least 60% of F3 patients) will be enrolled to receive either denifanstat 50 mg (580 patients), placebo (580 patients), or denifanstat 25 mg (100 patients).

02

Conditions studied

  • MASH
  • NASH
  • Metabolic Dysfunction-associated Steatohepatitis
  • Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Nonalcoholic Fatty Liver

Keywords

  • fibrosis
  • fatty liver
  • steatohepatitis
03

In context

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Lead sponsor

Sagimet Biosciences Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Willing and able to participate in the study and provide written .
  2. Adults between 18 and 75 years of age.
  3. (BMI) ≥23 kg/m\^2 for Asian patients and ≥25 kg/m\^2 for patients of other races.
  4. Presence of metabolic risk factor(s), as follows:

    1. T2DM.

      OR

    2. 2 out of 4 of the following:

      • BMI ≥30 kg/m\^2.
      • Hypertension, or on active antihypertensive treatment.
      • Elevated fasting serum TGs or on active treatment for hypertriglyceridemia.
      • Reduced fasting serum HDL-c or on active treatment for dyslipidemia.
  5. For patients with T2DM:

    • ≤9.5%.
    • Metformin, insulin, dipeptidyl peptidase-4 inhibitors (DPP4-Is), sodium-glucose transport protein-2 inhibitors (SGLT2-Is), and alpha-glucosidase inhibitors (α-GIs): stable dose for at least 12 weeks prior to qualifying liver and screening.
    • Sulfonylureas (SUs) and glinides: stable dose with no history of relevant hypoglycemia for at least 12 weeks prior to qualifying liver biopsy and screening.
    • GLP-1 RA: stable dose for at least 18 weeks prior to start of screening.
  6. Noncirrhotic, biopsy-proven MASH with:

    1. A fibrosis stage of F2 or F3.
    2. NAS ≥4 with at least a score of 1 in each of the following NAS components:

      • Steatosis (scored 0 to 3).
      • Hepatocyte ballooning (scored 0 to 2).
      • Lobular inflammation (scored 0 to 3).
  7. A qualifying historical liver biopsy within 6 months before the screening visit. Historical biopsy results will be confirmed by central reading.

    If there is no available historical liver biopsy within this time period, a liver biopsy must be performed during the screening period. Patients should be deemed likely to have MASH F2/F3 fibrosis prior to proceeding to a liver biopsy, as indicated by the following:

    1. FibroScan.

      • Liver stiffness measurement (LSM) ≥8.5 kPa.
      • Controlled attenuation parameter (CAP) ≥280 dB/m.
    2. (AST) >20 U/L.
  8. Stable ALT and AST levels.

Exclusion Criteria:

  1. Previous intake of an approved MASH medication.
  2. Exclusionary laboratory values:

    1. ALT and/or AST >5 × .
    2. ALP ≥2 × ULN.
    3. Total serum concentration >1.3 mg/dL.
    4. Serum albumin concentration \<3.5 g/dL.
    5. >1.3 except for patients receiving anticoagulant treatment.
    6. count \<140,000/μL.
    7. Fasting TG level ≥500 mg/dL.
    8. \<45 mL/min/1.73 m\^2.
  3. History of excessive alcohol intake for a period of more than 3 consecutive months within 1 year prior to screening.
  4. Presence of cirrhosis on liver histology according to the assessment of the central reader.
  5. Current or historical clinically evident hepatic decompensation.
  6. Evidence of another form of active liver disease.
  7. Positive serologic evidence of current infectious liver disease.
  8. MELD score ≥12.
  9. Planned or history of liver transplantation.
  10. Prior or planned bariatric surgery.
  11. Gain or loss of >5% of body weight in the 3 months or >10% of body weight in the 6 months prior to screening, qualifying liver biopsy, and the baseline visit (V1).
  12. Any of the following within 6 months prior to the baseline visit (V1):

    1. Myocardial infarction.
    2. CABG/PTCA.
    3. Unstable angina.
    4. , stroke, or cerebrovascular disease.
  13. Unstable or undiagnosed arrhythmias.
  14. Uncontrolled high BP.
  15. with a complete remission date within 5 years prior to the baseline visit (V1).
  16. Any current or history of hepatocellular carcinoma.
  17. Diabetes other than T2DM.
  18. Uncontrolled hypothyroidism.
  19. Any other known serious disease or other disease which in the Investigator's opinion would exclude the patient from participating in the study.
  20. Previous intake of an approved MASH medication, unless there is at least a 6-month between the last date of intake of the approved MASH medication and date of screening.
  21. Use of a nonpermitted concomitant medication within 30 days or 5 half-lives prior to the qualifying liver biopsy and screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Denifanstat 50 mg

    Denifanstat tablet, orally, once daily

    Drug: Denifanstat

  • Experimental
    Denifanstat 25 mg

    Denifanstat tablet, orally, once daily

    Drug: Denifanstat

  • Placebo comparator
    Placebo

    Placebo tablet, orally, once daily

    Drug: Placebo

Interventions

  • Tablet

    Also known as: TVB-2640

  • DrugPlacebo

    Matching Tablet

06

What researchers measure

Primary outcomes

  1. Dual Primary Efficacy Endpoint 1: Interim Analysis: MASH Resolution (denifanstat 50 mg compared to placebo)

    Proportion of patients who achieve MASH resolution (defined as NAS\* of 0 for ballooning, and 0 or 1 for inflammation) without worsening of fibrosis stage at Week 52. \*NAS: nonalcoholic fatty liver disease activity score

    Time frame: 52 weeks

  2. Dual Primary Efficacy Endpoint 2: Interim Analysis: Improvement in Fibrosis (denifanstat 50 mg compared to placebo)

    Proportion of patients who achieve at least a 1-point improvement in fibrosis stage and without worsening of steatohepatitis (defined as no increase in NAS\* for ballooning, inflammation, or steatosis) at Week 52.

    Time frame: 52 weeks

  3. Primary Endpoint: End of Study Analysis: Liver-related Composite Clinical Outcome (denifanstat 50 mg compared to placebo)

    Time to first occurrence of any event from the following composite clinical outcome: death from any cause; histopathologic progression to cirrhosis; liver transplant; Model for End-Stage Liver Disease (MELD) score ≥15; Liver decompensation event defined by: Ascites requiring chronic diuretic treatment, Hepatic encephalopathy grade 2 or above requiring at least a 24-hour hospitalization, Variceal hemorrhage requiring hospitalization and transfusion of blood.

    Time frame: 234 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Dec 2030, 69 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 19, 2024
StartEst.
Mar 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06594523
Lead sponsor
Sagimet Biosciences Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Mar 2025 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion